"TARE-Y90 should be considered effective and feasible for children with liver cancers and has the potential to be used earlier in treatment, alongside chemotherapy, to help reduce tumor size to provide better surgical treatment options and improved prognosis," said Aguado. "I am fortunate to be part of the Nemours Liver Tumor Treatment Team, working alongside world the renowned pediatric liver specialists, Dr. Howard Katzenstein and Dr. Stephen Dunn, to add interventional radiology to help care for children with liver tumors."
In the study, the authors note several limitations, including the retrospective nature of the research, as well as the potential for selection bias in the patients treated, as patients were only included if they had chemoresistant, nonsurgical disease, without case-control for comparison.
About Nemours Children's Health System
Nemours is an internationally recognized children's health system that owns and operates the two free-standing children's hospitals: the Nemours/Alfred I. duPont Hospital for Children in Wilmington, Del., and Nemours Children's Hospital in Orlando, Fla., along with outpatient facilities in five states, delivering pediatric primary, specialty and urgent care. Nemours also powers the world's most-visited website for information on the health of children and teens, KidsHealth.org, and offers on-demand, online video patient visits through Nemours CareConnect. Nemours ReadingBrightstart.org is a program dedicated to preventing reading failure in young children, grounded in Nemours' understanding that child health and learning are inextricably linked, and that reading level is a strong predictor of adult health.
Established as The Nemours Foundation through the legacy and philanthropy of Alfred I. duPont, Nemours provides pediatric clinical care, research, education, advocacy and prevention programs to families in the communities it serves.
Back to HCB News
